Bryan Minihan:
Internal: 702 3511
External: 1 919 282 3511

Email me

Chief Executive Officer

JP Garnier is Chief Executive Officer of GlaxoSmithKline. He assumed this role in January 2001 with the merger of SmithKline Beecham and Glaxo Wellcome. He joined SmithKline Beecham in 1990 as President of its pharmaceutical business in North America and served as Chairman, Pharmaceuticals from 1994 until his appointment as Chief Operating Officer in 1995. He was elected to the company's Board of Directors in 1992. He became Chief Executive Officer of SmithKline Beecham in April 2000.

Prior to SmithKline Beecham, JP served as President of Schering-Plough's US business. During his 15 years at Schering, he held various management positions, including General Manager of several overseas subsidiaries. In 1983, he joined the US Pharmaceutical Products Division serving as Vice President of Marketing. He was then named Senior Vice President and General Manager of the OTC business and assumed responsibility for sales and marketing for the US prescription business prior to becoming President.

JP serves on the boards of directors of the United Technologies Corporation, Committee to Encourage Corporate Philanthropy and the Eisenhower Exchange Fellowships, Inc. In January 1997, JP was selected by President Chirac of France to receive the Chevalier de la Légion d'Honneur. Founded in 1802 by France's Emperor Napoleon I, the Légion honours individuals for their civilian or military accomplishments. In April 1997, he received from the Cancer Research Institute the Oliver R Grace Award for Distinguished Service in Advancing Cancer Research. In 2001, he was named one of 50 "Stars of Europe" by BusinessWeek magazine and presented with the Marco Polo Award for GlaxoSmithKline's commitment to China. In 2002, he received the Humanitarian Award from the Sabin Vaccine Institute. In 2005, he was presented with the Global Business Leadership Award from Stanford Business School, and awarded the Global Corporate Citizenship Award from AMREF (African Medical and Research Foundation). In 2006, he was named to the global list of top 20 CEOs by the Best Practice Institute and appointed to Chancellor Gordon Brown's UK Advisory Council.

JP holds a PhD in pharmacology and an MS in pharmaceutical science from the University of Louis Pasteur in France. As a Fulbright Scholar, he earned an MBA at Stanford University, California, in 1974. In 2002, he was honoured with the Fulbright Association's Lifetime Achievement Medal.